Exchange: NYSE·Updated 01:40 PM EDT
TEVA logo

TEVATeva- Pharmaceutical Industries Ltd. - ADR

$30.71
$0.56
(1.86%)
Today
EarningsJul 29
Mkt Cap$35.11B
Vol1.7M
News
all
press releases
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.
Zacks
More News
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
JNJ is set to report second-quarter results on July 15 as investors weigh strong growth drivers, new launches and patent headwinds shaping its long-term outlook.
Zacks
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Teva And Samsung Bioepis Enter Commercialization Agreement For OPUVIZ In Canada
(RTTNews) - On Thursday, Teva Pharmaceutical Industries Ltd. (TEVA) and Samsung Bioepis Co., Ltd., a unit of Samsung Epis Holdings Co. Ltd. (0126Z0.KS), announced that they have entered into a license and commercialization agreement for OPUVIZ in Canada...
Nasdaq News: Markets
Teva And Polpharma Biologics Ink Global Licensing Deal For Ocrevus Biosimilar
(RTTNews) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA) and Polpharma Biologics International AG announced Thursday a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma B...
Nasdaq News: Markets
Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?
Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update...
Yahoo! Finance: News
Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results?
Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results...
Yahoo! Finance: News
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.
Zacks
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth
TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix.
Zacks
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome
TEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette syndrome.
Zacks
<
1
2
...
>

Advertisement|Remove ads.